Table 1.
Baseline characteristics
| Baseline T-score-2-0 or greater |
Baseline T-score less than-2-0 |
|||
|---|---|---|---|---|
| Exemestane (n=147) | Anastrozole (n=153) | Exemestane (n=101) | Anastrozole (n=96) | |
| Age at allocation (years) | ||||
| 40-49 | 4 (3%) | 4 (3%) | 1 (1%) | 0 (0%) |
| 50-59 | 50 (34%) | 59 (39%) | 21 (21%) | 15 (16%) |
| 60-69 | 52 (35%) | 63 (41%) | 37 (37%) | 28 (29%) |
| 70-79 | 34 (23%) | 17 (11%) | 31 (31%) | 42 (44%) |
| ≥80 | 7 (5%) | 10 (7%) | 11 (11%) | 11 (11%) |
| Median age (IQR; years) | 63.2 (58.1-70.9) | 62.0 (57.1-68.2) | 68.3 (61.1-73.7) | 71.0 (61.9-77.0) |
| Ethnic origin | ||||
| Data missing | 0 (0%) | 2 (1%) | 3 (3%) | 3 (3%) |
| White | 141 (96%) | 141 (92%) | 90 (89%) | 86 (90%) |
| Black | 4 (3%) | 7 (5%) | 4 (4%) | 3 (3%) |
| Asian | 1 (1%) | 1 (1%) | 4 (4%) | 3 (3%) |
| Unknown | 1 (1%) | 2 (1%) | 0 (0%) | 1 (1%) |
| ECOG performance status score | ||||
| 0 (fully) | 130 (88%) | 136 (89%) | 75 (74%) | 76 (79%) |
| 1 (restricted) | 15 (10%) | 17 (11%) | 23 (23%) | 20 (21%) |
| ≥2 (ambulatory) | 2 (1%) | 0 (0%) | 3 (3%) | 0 (0%) |
| Postmenopausal status | ||||
| Bilateral oophorectomy | 11 (7%) | 14 (9%) | 2 (2%) | 7 (7%) |
| Age ≥60 years | 89 (61%) | 88 (58%) | 79 (78%) | 77 (80%) |
| Age 45-59 years (<12 months since last menstruation; hysterectomy) | 5 (3%) | 9 (6%) | 2 (2%) | 2 (2%) |
| 45-59 years (>12 months) | 41 (28%) | 40 (26%) | 17 (17%) | 10 (10%) |
| 45-59 (<12 months; HRT) | 1 (1%) | 2 (1%) | 1 (1%) | 0 (0%) |
| Type of most extensive primary surgery | ||||
| Partial mastectomy | 111 (76%) | 113 (74%) | 61 (60%) | 55 (57%) |
| Mastectomy (not otherwise specified) | 36 (24%) | 40 (26%) | 40 (40%) | 41 (43%) |
| Axillary dissection | ||||
| No | 95 (65%) | 89 (58%) | 57 (56%) | 55 (57%) |
| Yes | 52 (35%) | 64 (42%) | 44 (44%) | 41 (43%) |
| Tumour laterality | ||||
| Bilateral | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Left | 77 (52%) | 83 (54%) | 59 (58%) | 52 (54%) |
| Right | 69 (47%) | 70 (46%) | 42 (42%) | 44 (46%) |
| Oestrogen-receptor status | ||||
| Negative | 1 (1%) | 1 (1%) | 0 (0%) | 1 (1%) |
| Positive | 146 (99%) | 152 (99%) | 101 (100%) | 95 (99%) |
| Progesterone-receptor status | ||||
| Negative | 18 (12%) | 25 (16%) | 19 (19%) | 22 (23%) |
| Positive | 129 (88%) | 128 (84%) | 82 (81%) | 74 (77%) |
| T stage | ||||
| T1 | 113 (77%) | 115 (75%) | 67 (66%) | 72 (75%) |
| T2 | 29 (20%) | 33 (22%) | 30 (30%) | 22 (23%) |
| T3 | 5 (3%) | 5 (3%) | 3 (3%) | 2 (2%) |
| TX | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) |
| N stage | ||||
| N0 | 117 (80%) | 112 (73%) | 71 (70%) | 67 (70%) |
| N1 | 21 (14%) | 30 (20%) | 26 (26%) | 22 (23%) |
| N2 | 7 (5%) | 7 (5%) | 2 (2%) | 3 (3%) |
| N3 | 0 (0%) | 1 (1%) | 0 (0%) | 2 (2%) |
| NX | 2 (1%) | 3 (2%) | 2 (2%) | 2 (2%) |
| Previous adjuvant chemotherapy | ||||
| No | 101 (69%) | 97 (63%) | 73 (72%) | 73 (76%) |
| Yes | 46 (31%) | 56 (37%) | 28 (28%) | 23 (24%) |
| Previous raloxifene treatment | ||||
| No | 143 (97%) | 152 (99%) | 99 (98%) | 94 (98%) |
| Yes | 2 (1%) | 1 (1%) | 2 (2%) | 2 (2%) |
| Unknown | 2 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Radiotherapy (previous or concurrent) | ||||
| Unknown or missing data | 1 (1%) | 0 (0%) | 1 (1%) | 1 (1%) |
| Yes | 115 (78%) | 115 (75%) | 63 (62%) | 54 (56%) |
| No | 31 (21%) | 38 (25%) | 37 (37%) | 41 (43%) |
| Fractures within 10 years before allocation? | ||||
| No | 130 (88%) | 143 (93%) | 91 (90%) | 79 (82%) |
| Yes | 17 (12%) | 10 (7%) | 10 (10%) | 17 (18%) |
| Cardiovascular history | ||||
| None | 55 (37%) | 58 (38%) | 52 (51%) | 47 (49%) |
| Ischaemia | 92 (63%) | 95 (62%) | 49 (49%) | 49 (51%) |
| Median bone mineral density index T-score (IQR) | ||||
| Hip | −0.1 (−0.8 to 0.6) | −0.4 (−0.9 to 0.5) | −1.9 (−2.5 to −1.3) | −1.8 (−2.3 to −1.3) |
| Lumbar spine | −0.1 (−0.9 to 0.9) | −0.2 (−1.0 to 0.6) | −2.3 (−2.8 to −1.7) | −2.4 (−2.7 to −2.1) |
| Bisphosphonate use | ||||
| No | 145 (99%) | 148 (97%) | 5 (5%) | 5 (5%) |
| Yes | 2 (1%) | 5 (3%) | 96 (95%) | 91 (95%) |
Data are n (%), unless stated otherwise. ECOG=Eastern Cooperative Oncology Group. HRT=hormone replacement treatment.